Draft remit: To appraise the clinical and cost effectiveness of NBTXR-3 within its CE marked indication for neoadjuvant treatment of soft tissue sarcoma.
Status In progress
Process STA pre-2018
ID number 1050

Provisional Schedule

The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of NBTXR-3 for treating soft tissue sarcoma ID1050. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal. The consultation on the draft scope closed on Tuesday 19 December 2017. After careful review of the consultation comments received NICE has agreed that a scoping workshop would not be appropriate. As a consequence of this the scoping workshop arranged for Thursday 11 January 2018 at 14:00.has been cancelled. NICE will still submit a report to the Department of Health summarising the results of the consultation. The report will help ministers to decide whether or not the technology should be formally referred to NICE for appraisal. If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar via email at michelle.adhemar@nice.org.uk 21 December 2018
Committee meeting: 1 30 May 2019
Expected publication 23 October 2019

Project Team

Project lead Jeremy Powell

Email enquiries


Companies sponsors Nanobiotix (NBTXR-3)
Others Department of Health and Social Care
  NHS England
  NHS North Durham CCG
  NHS Stockport CCG
  Welsh Government
Patient carer groups Black Health Agency
  Cancer 52
  Cancer Black Care
  Cancer Equality
  GIST Support UK
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  Sarcoma UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Anaesthetists
  Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  British Geriatrics Society
  British Psychosocial Oncology Society
  British Sarcoma Group
  Cancer Research UK
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society


Associated public health groups Public Health England
  Public Health Wales
Comparator companies none
General commentators Allied Health Professionals Federation
  All Wales Therapeutics and Toxicology Centre
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
05 October 2018 Invitation to participate
21 November 2017 - 19 December 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
11 August 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance